664304-83-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(trifluoroMethyl)-2-Pyrrolidinone is used as a solvent for the production of various pharmaceuticals, facilitating the manufacturing process and improving the solubility of active ingredients.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(trifluoroMethyl)-2-Pyrrolidinone serves as a solvent, aiding in the formulation of effective agrochemical products that enhance crop protection and yield.
Used in Electronic Materials Production:
4-(trifluoroMethyl)-2-Pyrrolidinone is utilized as a solvent in the production of electronic materials, contributing to the development of advanced technologies and devices.
Used as a Chemical Intermediate:
4-(trifluoroMethyl)-2-Pyrrolidinone is used as an intermediate in the synthesis of other chemicals, particularly in the creation of new pharmaceuticals and agrochemicals, expanding the range of available products and treatments.
Used in Antimicrobial Formulations:
Due to its antimicrobial properties, 4-(trifluoroMethyl)-2-Pyrrolidinone has potential applications in antimicrobial formulations, offering a broad-spectrum solution for controlling microbial growth in various settings.
It is crucial to handle 4-(trifluoroMethyl)-2-Pyrrolidinone with care, as it can cause skin, eye, and respiratory irritation if proper safety measures are not taken.

Upstream product

• 328-62-1 4,4,4-trifluoro-3-(nitromethyl)butyric acid ethyl ester 
• 911783-85-2 ethyl 4-amino-3-(3-trifluoromethyl)butanoate 

Downstream Products

• 1610033-81-2 1-(4-bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-one 

Relevant academic research and scientific papers

Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity

(S)-α-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB S.A.), a structural analogue of piracetam, has recently been approved as an add-on treatment of refractory partial onset seizures in adults. This drug appears to combine significant efficacy and high tolerability due to a unique mechanism of action. The latter relates to a brain-specific binding site for 2 (LBS for levetiracetam binding site) that probably plays a major role in its antiepileptic properties. Using this novel molecular target, we initiated a drug-discovery program searching for ligands with significant affinity to LBS with the aim to characterize their therapeutic potential in epilepsy and other central nervous system diseases. We systematically investigated the various positions of the pyrrolidone acetamide scaffold. We found that (i) the carboxamide moiety on 2 is essential for affinity; (ii) among 100 different side chains, the preferred substitution α to the carboxamide is an ethyl group with the (S)-configuration; (iii) the 2-oxopyrrolidine ring is preferred over piperidine analogues or acyclic compounds; (iv) substitution of positions 3 or 5 of the lactam ring decreases the LBS affinity; and (v) 4-substitution of the lactam ring by small hydrophobic groups improves the in vitro and in vivo potency. Six interesting candidates substituted in the 4-position have been shown to be more potent antiseizure agents in vivo than 2. Further pharmacological studies from our group led to the selection of (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide 83α (ucb 34714) as the most interesting candidate. It is approximately 10 times more potent than 2 as an antiseizure agent in audiogenic seizure-prone mice. A clinical phase I program has been successfully concluded and 83α will commence several phase II trials during 2003.